Navigation Links
Siteman Cancer Center at Barnes-Jewish and Washington University Begins Imaging with First ViewRay System

CLEVELAND, July 11, 2012 /PRNewswire/ -- Investigators at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri, have begun studying the imaging capabilities of an innovative radiation therapy system from ViewRay™ Incorporated. The ViewRay system is the first comprehensive image-guided radiation therapy system, providing a patented combination of simultaneous radiotherapy delivery and continuous magnetic resonance imaging (MRI) for the treatment of cancer. The Siteman Cancer Center is a national leader in the early adoption and use of advanced treatments for cancer patients.

The Siteman Cancer Center's clinical research began in January 2012, when imaging and simulated treatments were completed on the ViewRay system with a group of volunteer patients. Support for the research was partially provided by ViewRay. The purpose of the study was to assess the quality of images captured by ViewRay's MRI technology. The internal study involved 27 patients with various types of cancer, including lung, head and neck, breast, and prostate cancer. Most patients were scanned twice.

"It is important to evaluate any new technology early to assess potential clinical impacts," said Parag J. Parikh, MD, assistant professor of radiation oncology at the Siteman Cancer Center and lead investigator for the study. "We are comparing the new images with available radiation oncology imaging techniques and will report the results at upcoming scientific meetings."

High-quality soft-tissue imaging is an essential feature of the ViewRay system: MR images are used to plan treatments, position patients for treatment, and track each patient's position during treatment. "When physicians can clearly see the target, we are better able to adapt the treatment to changes in the patient's anatomy," said ViewRay Chief Medical Officer Prabhakar Tripuraneni, MD, FACR, FASTRO. "By verifying the high quality of the ViewRay system's images, the Siteman study establishes the potential value of MRI-guided radiation therapy."

ViewRay's integrated imaging and radiotherapy delivery system received marketing clearance from the U.S. FDA in May 2012.

About ViewRay
ViewRay Incorporated of Cleveland, Ohio, is a privately held medical device company developing advanced radiation therapy technology for the treatment of cancer. The ViewRay system provides continuous soft-tissue imaging during treatment, using MRI-guided radiotherapy, so that clinicians are able to see where the actual radiation dose is being delivered and adapt to changes in the patient's anatomy. For more information, visit

About the Siteman Cancer Center
The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine is the only National Cancer Institute Comprehensive Cancer Center in Missouri and within a 240-mile radius of St. Louis. Siteman is also one of only 20 national members of the National Comprehensive Cancer Network, an alliance of the world's leading cancer centers dedicated to improving the quality, effectiveness and efficiency of oncology practice so patients can live better lives. For more information, visit

ViewRay is a trademark of ViewRay Incorporated.

ViewRay acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier Commission, which provided funding in support of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance Project.



SOURCE ViewRay Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BSGI Molecular Breast Imaging Proves Equivalent to MRI in Breast Cancer Patient Management
2. BSGI Molecular Breast Imaging Provides Better Results than MRI for Cancer Patients with Dense Breasts
3. Relief from Menopause Symptoms Short-lived for Prempro Women Suffering from Cancers
4. Cancer Cell Article Demonstrates First Definitive Evidence for Targeting of Pol I as New Approach to Cancer Therapy
5. QIAGEN Achieves Personalized Healthcare Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
6. Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
7. Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
8. Global Kidney Cancer Drugs Industry
9. Trovagene to Study Trans-Renal KRAS Mutation Detection in Pancreatic Cancer
10. Prostate Cancer Center of New Jersey the Latest Center to Achieve High Honor of ACR-ASTRO Accreditation
11. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
Post Your Comments:
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
(Date:6/23/2016)... The Biotechnology industry might still ... great opportunities to investors. assesses the recent performances ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... your complimentary trade alerts at: ...
(Date:6/23/2016)... , June 23, 2016 Leading BioSciences ... address medical conditions resulting from a breakdown of ... appointed Greg Doyle as chief executive ... BioSciences, executive management team and board of directors, ... financial officer. He will provide continued leadership and ...
Breaking Medicine Technology:
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from reveals that behind the ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
Breaking Medicine News(10 mins):